BioSpace News Archive

Career Advice

4 Things That Could Scare Off a Potential Employer

Most of the interview process is out of your hands, for better or for worse. But what you can control are your actions.

October 31, 2019
·
3 min read
·
Laura Brothers
Business

Dicerna and Roche Partner on RNA Silencing for Hepatitis B in $1.67 Billion Deal

Under the terms of the deal, Roche will pay Dicerna $200 million upfront and up to another $1.47 billion for various development, regulatory and commercial milestones.

October 31, 2019
·
2 min read
·
Mark Terry
Policy

Appeals Court Upholds Decision in Merck and Gilead’s $2.54 Billion Patent Fight

A disappointed Merck said it was reviewing its options for a possible appeal, while a pleased Gilead said if an appeal came, it was confident a higher court would come to the same verdict as the federal appeals court.

October 31, 2019
·
2 min read
·
Alex Keown
BioMidwest

Research Roundup: What Are Microproteins and What Do They Do and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

October 31, 2019
·
5 min read
·
Mark Terry
Pharm Country

J&J’s Experimental Ebola Vaccine to be Deployed in the Congo to Help Stem Outbreak

In the Congo, there have been more than 3,000 cases and 2,000 related deaths to the Ebola virus outbreak.

October 31, 2019
·
3 min read
·
Alex Keown
Biotech Beach

DCN Dx and QIAGEN Lake Constance announce winner of the Rapid Testing Innovation Award

Luminostics, Inc., to receive $10,000 cash prize and recognition from the rapid point-of-care diagnostics industry

October 31, 2019
·
3 min read
Drug Development

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.

October 31, 2019
·
5 min read
Pharm Country

J&J’s HIV Drug Edurant and Other Similar Drugs May Be Effective in Treating Zika Viruses

Researchers with Temple University Health System have found that the Zika virus responds to an HIV drug called rilpivirine, which is marketed by Janssen, a Johnson & Johnson company, as Edurant.

October 31, 2019
·
2 min read
·
Mark Terry
Oooooh, That’s Scary! Welcome to the Dark Side of Biopharma

This Halloween, BioSpace has collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

October 31, 2019
·
7 min read
·
Alex Keown and Mark Terry
Drug Development

SurgiMab’s Fluorescent Agent Could Improve Colorectal Cancer Surgery

The agent is an antibody-based fluorescence-guided approach aimed at improving surgery and clinical outcomes.

October 31, 2019
·
2 min read
·
Alex Keown